Novo Nordisk to buy Akero for up to $5.2 billion as new CEO bets on liver drug candidate

1. Novo Nordisk to acquire Akero for $5.2 billion for liver disease drug. 2. Offer includes $54 per share, 16.2% premium to last close. 3. Efruxifermin may become a cornerstone treatment for fatty liver disease. 4. Novo's acquisition escalates deal sizes amid heavy investor scrutiny. 5. Akero's shares rose nearly 18% in premarket trading post-announcement.